Gastrointestinal Cancer Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Trials Currently Recruiting Participants - Gastrointestinal Cancer Committee

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EA2142	Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas	Jennifer R. Eads, MD, Chair George Fisher, MD, PhD, Co-Chair (Paul J. Catalano, ScD)	126	11/06/2015	EA2142 Resources
EA2165	A Randomized Phase II Study of Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage 11-111 B Anal Cancer	Lakshmi N. Rajdev, MD, Chair Peter J. O'Dwyer, MD, Co-Chair Al B. Benson, III, MD, Co-Chair (Paul J. Catalano, ScD)	200	04/13/2018	EA2165 Resources
EA2174	A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma	Jennifer R. Eads, MD, Chair Michael K. Gibson, MD, PhD, Co-Chair Lakshmi N. Rajdev, MD, Co-Chair (Paul J. Catalano, ScD)	278	01/17/2019	EA2174 Resources
EA2176	A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients	Cathy Eng, MD, Chair Al B. Benson, III, MD, Co-Chair Kristen Ciombor, MD, Co-Chair (Paul J. Catalano, ScD)	205	10/15/2020	EA2176 Resources
EA2182	A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)	Jennifer Dorth, MD, Chair Cathy Eng, MD, Co-Chair Joshua E. Meyer, MD, Co-Chair (Paul J. Catalano, ScD)	252	11/12/2019	EA2182 Resources
EA2183	A Phase 3 Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)	Nataliya V. Uboha, MD, PhD, Chair Lakshmi N. Rajdev, MD, Co-Chair (Michelle Weitz MS)	Step One 314 Step Two 204	02/06/2020	EA2183 Resources
EA2185	Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs	David S. Weinberg, MD, Chair Herbert J. Zeh, MD, Co-Chair (Constantine A. Gatsonis, PhD)	4606	01/16/2020	EA2185 Resources
EA2186	A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)	Efrat Dotan, MD, Chair (Paul J. Catalano, ScD)	184	06/18/2020	EA2186 Resources
EA2187	A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma	Dustin A. Deming, MD, Chair Anita A. Turk, MD, Co-Chair (Paul J. Catalano, ScD)	52	01/31/2020	EA2187 Resources
EA2197	Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial	Shishir K. Maithel, MD, Chair (Michelle Weitz, MS)	186	12/22/2020	EA2197 Resources
7151	Incidence and Significance of Extracolonic Findings on CT Colonography: Retrospective Analysis of National CT Colonography Trial Data *Patient recruitment by invitation only* Note: This trial is a substudy of A6664, the national CT colonography screening trial of healthy participants. A7151 is funded by the ACRIN Fund for Imaging Innovation.	Hanna M. Zafar, MD, Chair William C. Black, MD, Co-Chair (Jeremy Gorelick, PhD)	520	09/16/2011	7151 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL MATERIALS

EA2142 Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Jennifer R. Eads, MD, Chair
George Fisher, MD, PhD, Co-Chair
(Paul J. Catalano, ScD) 126 11/06/2015 EA2142 Resources

EA2165 A Randomized Phase II Study of Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage 11-111 B Anal Cancer Lakshmi N. Rajdev, MD, Chair
Peter J. O'Dwyer, MD, Co-Chair
Al B. Benson, III, MD, Co-Chair
(Paul J. Catalano, ScD) 200 04/13/2018 EA2165 Resources

EA2174 A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Jennifer R. Eads, MD, Chair
Michael K. Gibson, MD, PhD, Co-Chair
Lakshmi N. Rajdev, MD, Co-Chair
(Paul J. Catalano, ScD) 278 01/17/2019 EA2174 Resources

EA2176 A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients Cathy Eng, MD, Chair
Al B. Benson, III, MD, Co-Chair
Kristen Ciombor, MD, Co-Chair
(Paul J. Catalano, ScD) 205 10/15/2020 EA2176 Resources

EA2182 A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Jennifer Dorth, MD, Chair
Cathy Eng, MD, Co-Chair
Joshua E. Meyer, MD, Co-Chair
(Paul J. Catalano, ScD) 252 11/12/2019 EA2182 Resources

EA2183 A Phase 3 Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA) Nataliya V. Uboha, MD, PhD, Chair
Lakshmi N. Rajdev, MD, Co-Chair
(Michelle Weitz MS) Step One 314
Step Two 204 02/06/2020 EA2183 Resources

EA2185 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs David S. Weinberg, MD, Chair
Herbert J. Zeh, MD, Co-Chair
(Constantine A. Gatsonis, PhD) 4606 01/16/2020 EA2185 Resources

EA2186 A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) Efrat Dotan, MD, Chair
(Paul J. Catalano, ScD) 184 06/18/2020 EA2186 Resources

EA2187 A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma Dustin A. Deming, MD, Chair
Anita A. Turk, MD, Co-Chair
(Paul J. Catalano, ScD) 52 01/31/2020 EA2187 Resources

EA2197 Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial Shishir K. Maithel, MD, Chair
(Michelle Weitz, MS) 186 12/22/2020 EA2197 Resources

7151 Incidence and Significance of Extracolonic Findings on CT Colonography: Retrospective Analysis of National CT Colonography Trial Data

***Patient recruitment by invitation only***

Note: This trial is a substudy of A6664, the national CT colonography screening trial of healthy participants. A7151 is funded by the ACRIN Fund for Imaging Innovation. Hanna M. Zafar, MD, Chair
William C. Black, MD, Co-Chair
(Jeremy Gorelick, PhD) 520 09/16/2011 7151 Resources

Download